Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 9:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 1,466 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Control Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults

NCT03529773
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Formulation A, Formulation B, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
40
States / cities
Mobile, Alabama • Anaheim, California • La Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 27, 2026, 9:56 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of a New Treatment for Recurrent Symptoms of Oral Herpes Virus Infection

NCT01308424
View directory record Official record
Conditions
Oral Herpes Simplex
Interventions
BTL TML HSV, Matching placebo
Drug
Lead sponsor
Beech Tree Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Lexington, Kentucky • Buffalo, New York • Norwich, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Oct 27, 2026, 9:56 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia

NCT02282215
View directory record Official record
Conditions
Acute Myeloid Leukemia, Neutropenia, Infection
Interventions
CLT-008, G-CSF
Biological
Lead sponsor
Cellerant Therapeutics
Industry
Eligibility
55 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 27, 2026, 9:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

STI/HIV Intervention Behavioral Intervention Program

NCT04547413
View directory record Official record
Conditions
Sexually Transmitted Infections
Interventions
STI/HIV Intervention Behavioral Intervention Program
Behavioral
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years to 30 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Fayetteville, North Carolina • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 27, 2026, 9:56 PM EDT
Active, not recruiting Not applicable Interventional

Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized Patients

NCT05688423
View directory record Official record
Conditions
Injection Site Infection, Substance Use Disorders
Interventions
SIRI Team, Treatment as Usual
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Miami, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 27, 2026, 9:56 PM EDT
Completed Not applicable Interventional

Tele-monitoring of Post Join Arthroplasty Outcomes: A Feasibility Study

NCT04586296
View directory record Official record
Conditions
Post-Op Complication
Interventions
Telemedicine
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 27, 2026, 9:56 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

NCT04933968
View directory record Official record
Conditions
Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection, Parainfluenza (PIV) Infection, Respiratory Syncytial Viral (RSV) Infection, Influenza Infection
Interventions
ALVR106, Placebo
Biological
Lead sponsor
AlloVir
Industry
Eligibility
17 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 27, 2026, 9:56 PM EDT
Completed Not applicable Interventional

Supplemental Perioperative Oxygen to Reduce Surgical Site Infection After High Energy Fracture Surgery

NCT01798810
View directory record Official record
Conditions
Post Operative Surgical Site Infection
Interventions
Supplemental Perioperative Oxygen
Procedure
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 80 Years
Enrollment
1,171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
Phoenix, Arizona • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 27, 2026, 9:56 PM EDT
Withdrawn Not applicable Interventional

Evaluating the Role of the Guidewire in Peripheral Intravenous Access

NCT04949854
View directory record Official record
Conditions
Peripheral Intravenous Vein Catheter Phlebitis, Intravenous Infection
Interventions
B.Braun 6.35 cm 20 Gauge ultralong intravenous catheter, B.D Accucath 5.71 cm 20 Gauge ultralong intravenous catheter
Device
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 27, 2026, 9:56 PM EDT
Recruiting Not applicable Interventional

Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis

NCT03704766
View directory record Official record
Conditions
Joint Infection, Infection of Hip Joint (Disorder), Infection of Shoulder Joint, Septic Arthritis
Interventions
Synovial Alpha-defensin assay, Synovial Neutrophil elastase assay, Synovial lactate assay, Synovial C-reactive Protein (CRP), Synovial Staphylococcus spp antigen panel, Synovial Candida spp antigen panel, Synovial Enterococcus faecalis assay, Synovial bacterial culture by BacT/Alert, Synovial Cell count + differential (CBC), Synovial Gram Stain, Synovial Leukocyte Esterase Test Strips, Synovial PCR for Kingella kingae, Serum Cell count + differential (CBC), Serum erythrocyte sedimentation rate (ESR), Serum C-reactive Protein (CRP), Serum D-dimer, Serum Procalcitonin, Blood Cultures, Optional blood testing per standard of care (ASO, anti-strep, ANA, anti-DS-DNA, HLA-B27, RF, Lyme and other inflammatory/ rheumatologic markers )
Diagnostic Test
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
Up to 17 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • New York, New York • Collierville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 27, 2026, 9:56 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection

NCT01059565
View directory record Official record
Conditions
Cystic Fibrosis, Burkholderia Infections
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
34
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 27, 2026, 9:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings

NCT04726371
View directory record Official record
Conditions
Intellectual Disability, Developmental Disability, Axis I Diagnosis, Mental Illness, Covid19, Coronavirus
Interventions
Generic Best Practices, Tailored Best Practices
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 27, 2026, 9:56 PM EDT
Terminated Phase 2 Interventional Results available

Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT)

NCT04999592
View directory record Official record
Conditions
Out-Of-Hospital Cardiac Arrest, Pneumonia
Interventions
Standard of care without prophylaxis, Antibiotic prophylaxis
Drug
Lead sponsor
David J. Gagnon
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 27, 2026, 9:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human PfSPZ-LARC2 Vaccination/CHMI

NCT06735209
View directory record Official record
Conditions
Malaria
Interventions
PfSPZ Vaccine, PfSPZ (7G8) Challenge, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 27, 2026, 9:56 PM EDT
Completed Phase 2 Interventional

Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients

NCT05174806
View directory record Official record
Conditions
Diabetic Foot Infection, Diabetic Foot
Interventions
Topical Pravibismane, Standard of Care
Drug · Other
Lead sponsor
Microbion Corporation
Industry
Eligibility
18 Years to 79 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Fresno, California • Dallas, Texas • McAllen, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 27, 2026, 9:56 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

NCT04223804
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), HIV Infection, HIV-1
Interventions
ABBV-181, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
Bakersfield, California • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Oct 27, 2026, 9:56 PM EDT
Terminated Phase 2 Interventional

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )

NCT04442178
View directory record Official record
Conditions
COVID-19, Lymphocytopenia
Interventions
CYT107, Placebo
Drug
Lead sponsor
Revimmune
Industry
Eligibility
25 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Gainesville, Florida • St Louis, Missouri • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2022 · Synced Oct 27, 2026, 9:56 PM EDT
Completed Not applicable Interventional Results available

Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection

NCT02707991
View directory record Official record
Conditions
HIV, Hepatitis C, Chronic
Interventions
Nurse Case Management
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Oct 27, 2026, 9:56 PM EDT
Terminated Phase 2 Interventional Results available

Study of Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection

NCT06585150
View directory record Official record
Conditions
RSV Infection
Interventions
Obeldesivir, Obeldesivir Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
121
States / cities
Birmingham, Alabama • Cullman, Alabama • Guntersville, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 27, 2026, 9:56 PM EDT
Completed Not applicable Interventional

A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease

NCT00002058
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Clofazimine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 9:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Developing a Dyadic Intervention for Sexually Transmitted Infection (STI)/HIV Prevention in Youth

NCT03275168
View directory record Official record
Conditions
Exposure to Sexually Transmissible Disorder (Event)
Interventions
Intervention, Individual evidence-based STI/HIV prevention intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
16 Years to 30 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 27, 2026, 9:56 PM EDT
Withdrawn No phase listed Observational

Impact of COVID-19 on the Incidence, Characteristics, Management and Outcome of Sepsis

NCT04698382
View directory record Official record
Conditions
Sepsis, Septic Shock
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 27, 2026, 9:56 PM EDT
Completed Phase 1 Interventional

A Placebo-Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Envelope Proteins of HIV-1 gp160 and gp120 in Children >= 1 Month Old With Asymptomatic HIV Infection

NCT00000762
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1MN, rgp120/HIV-1 SF-2, gp160 Vaccine (MicroGeneSys)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 18 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
33
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 27, 2026, 9:56 PM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Zidovudine in HIV-Infected Pregnant Women and Their Infants

NCT00000960
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 60 Years
Enrollment
1,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
58
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 27, 2026, 9:56 PM EDT